Tadalafil/tamsulosin - Hanmi Pharmaceutical

Drug Profile

Tadalafil/tamsulosin - Hanmi Pharmaceutical

Alternative Names: HCP 1303

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia; Erectile dysfunction

Most Recent Events

  • 01 May 2016 Hanmi Pharmaceutical completes a phase-III clinical trial in Benign prostatic hyperplasia in South Korea (PO) (NCT02667938)
  • 09 Oct 2015 Phase-III clinical trials in Erectile dysfunction in South Korea (PO)
  • 01 Mar 2015 Phase-III clinical trials in Benign prostatic hyperplasia in South Korea (PO) (NCT02667938)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top